BLAINJECTIONINJECTABLEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBREVANT (amivantamab-vmjw) is a bispecific antibody developed by Johnson & Johnson targeting EGFR and MET pathways in non-small cell lung cancer (NSCLC). It is designed to bind simultaneously to two different targets, enabling dual pathway inhibition in patients with specific EGFR or MET mutations.
$0.001BPart D
PeakProduct is at peak lifecycle stage; commercial teams are likely focused on market penetration and indication expansion rather than launch activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RYBREVANT offers exposure to high-value oncology commercialization in a peak lifecycle product with established market presence. Roles focus on deepening market penetration, managing payer relationships, and supporting precision medicine adoption in EGFR/MET-driven NSCLC.
Brand ManagerMedical Science Liaison
Worked on RYBREVANT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.